You have free access to this content

Cancer

Cover image for Vol. 117 Issue 18

15 September 2011

Volume 117, Issue 18

Pages 4103–4335

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    1. You have free access to this content
      Farewell, with gratitude (pages 4106–4107)

      Raphael E. Pollock

      Version of Record online: 2 SEP 2011 | DOI: 10.1002/cncr.26368

      • original image

      Dr. Raphael Pollock welcomes a new Editor-in-Chief and bids Cancer farewell.

    2. You have free access to this content
      Are we scanning testis cancer patients too often? (pages 4108–4111)

      Timothy Gilligan

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26026

      It has become clear that, as the number of testis cancer survivors has increased, radiation therapy and chemotherapy have increased the risk of developing second nongerm cell tumor malignancies. There is growing concern and some evidence that radiation from computed tomography scans also may increase that risk and that, currently, an unnecessarily high number of scans are being performed.

    3. You have free access to this content
      Deciphering surveillance, epidemiology, and end results data analysis : Are We Seeing the Whole Picture? (pages 4112–4115)

      Kate E. Oliver and John H. Farley

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26027

      The Surveillance, Epidemiology, and End Results (SEER) Program is not without inherent biases, which necessarily limit interpretation of the data. The evaluation of any revised surgical staging system using the SEER database has all the intrinsic drawbacks to conclusions drawn from population-based studies and should be interpreted with caution.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Comparison of radiation-induced fatigue across 3 different radiotherapeutic methods for early stage breast cancer (pages 4116–4124)

      Neil K. Taunk, Bruce G. Haffty, Sining Chen, Atif J. Khan, Carl Nelson, Dorothy Pierce and Sharad Goyal

      Version of Record online: 1 MAR 2011 | DOI: 10.1002/cncr.26013

      • original image
      • original image

      Radiation-induced fatigue is a common side effect of breast cancer radiotherapy. The authors found that this fatigue is positively associated with the field sizes utilized, and that there is reduced fatigue in accelerated partial breast irradiation compared with accelerated hypofractionated radiotherapy and standard whole breast radiotherapy.

    2. You have free access to this content
      Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer (pages 4125–4131)

      Devika Gajria, Kim Feigin, Lee K. Tan, Sujata Patil, Stephanie Geneus, Maria Theodoulou, Larry Norton, Clifford A. Hudis and Tiffany A. Traina

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.25992

      • original image

      In this trial, the authors evaluated the efficacy and safety of a capecitabine schedule in combination with bevacizumab for the treatment of metastatic breast cancer. Capecitabine administered for 7 days followed by a 7-day rest with bevacizumab had modest efficacy and an acceptable toxicity profile.

    3. You have free access to this content
      Impact of body mass index on clinical outcomes in triple-negative breast cancer (pages 4132–4140)

      Foluso O. Ademuyiwa, Adrienne Groman, Tracey O'Connor, Christine Ambrosone, Nancy Watroba and Stephen B. Edge

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26019

      • original image
      • original image

      The prognostic effects of body mass index on clinical outcome were evaluated in patients with triple-negative breast cancer. No significant correlation emerged between obesity and recurrence-free survival or overall survival among patients with triple-negative breast cancer after controlling for clinically significant factors.

    4. Endocrine Disease
      You have free access to this content
      Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor–mediated PI3K feedback loop activation via ERK1/2 and AKT (pages 4141–4154)

      Bernhard Svejda, Mark Kidd, Alexander Kazberouk, Ben Lawrence, Roswitha Pfragner and Irvin M. Modlin

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26011

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Small intestinal neuroendocrine tumor treatment with either the mammalian target of rapamycin (mTor) inhibitor RAD001 or in combination with octreotide has no antiproliferative effect based on activation of phosphorylated AKT and phosphorylated extracellular signal-regulated kinase 1/2 and growth factor–mediated regulatory escape. Differences in RAD001 response rates in localized versus metastatic cell lines suggested that pretreatment identification of different tumor sensitivity to mTOR inhibitors could provide the basis for individualized treatment.

    5. Gastrointestinal Disease
      You have free access to this content
      Prognostic web-based models for stage II and III colon cancer : A population and clinical trials-based validation of numeracy and adjuvant! online (pages 4155–4165)

      Sharlene Gill, Charles Loprinzi, Hagen Kennecke, Axel Grothey, Garth Nelson, Ryan Woods, Caroline Speers, Steven R. Alberts, Aditya Bardia, Michael J. O'Connell and Daniel J. Sargent

      Version of Record online: 1 MAR 2011 | DOI: 10.1002/cncr.26003

      • original image

      The authors evaluated 2 web-based calculators that are used widely to estimate the prognosis and potential benefit of adjuvant 5-fluorouracil–based therapy for patients with stage II and III colon cancer. In this independent validation analysis, the authors demonstrated that both tools had similar predictive performance and acceptable reliability for patients with stage III disease, but predictions for stage II colon cancer were slightly overestimated.

    6. You have free access to this content
      How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? (pages 4166–4174)

      Janneke A. Wilschut, Ewout W. Steyerberg, Monique E. van Leerdam, Iris Lansdorp-Vogelaar, J. Dik F. Habbema and Marjolein van Ballegooijen

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26009

      • original image
      • original image

      More differentiation is indicated in screening guidelines for individuals with various degrees of family history of colorectal cancer. Shorter screening intervals than currently recommended may be appropriate for individuals with ≥2 first-degree relatives, of whom 1 is diagnosed before the age of 50 years.

    7. You have free access to this content
      Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer (pages 4175–4183)

      Martha L. Slattery, Abbie Lundgreen, Jennifer S. Herrick, Roger K. Wolff and Bette J. Caan

      Version of Record online: 1 MAR 2011 | DOI: 10.1002/cncr.26018

      A summary score based on “at-risk” genotypes revealed a hazard rate ratio of 5.10 (95% confidence interval, 2.56-10.15) associated with individuals who had the greatest number of “at-risk” genotypes; for rectal cancer, the hazard rate ratio was 6.03 (95% confidence interval, 2.83-12.75). The findings suggested that the presence of several higher risk alleles in the transforming growth factor-β signaling pathway increase the likelihood of dying after a diagnosis of colon or rectal cancer.

    8. Genitourinary Disease
      You have free access to this content
      Population-level comparative effectiveness of laparoscopic versus open radical nephrectomy for patients with kidney cancer (pages 4184–4193)

      Hung-Jui Tan, J. Stuart Wolf Jr, Zaojun Ye, John T. Wei and David C. Miller

      Version of Record online: 1 MAR 2011 | DOI: 10.1002/cncr.26014

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Patients with kidney cancer treated with laparoscopic radical nephrectomy (LRN) were less likely to require intensive care or prolonged length of stay when compared with those treated with an open approach, supporting the convalescence benefits of laparoscopy. However, in-hospital mortality was greater for patients treated with LRN, suggesting a potentially unanticipated consequence of this technique and highlighting the need for long-term monitoring both during and after the widespread adoption of innovative surgical therapies.

    9. You have free access to this content
      A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma (pages 4194–4200)

      Andrea L. Harzstark, Eric J. Small, Vivian K. Weinberg, Janine Sun, Charles J. Ryan, Amy M. Lin, Lawrence Fong, Dion R. Brocks and Jonathan E. Rosenberg

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.25931

      Everolimus and sorafenib were combined in a phase 1 study in patients with metastatic clear cell renal cell carcinoma. The combination was found to be tolerable with no pharmacokinetic interaction and with evidence of antitumor activity in previously untreated patients.

    10. You have free access to this content
      D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta (pages 4201–4211)

      Xiaopan Li, Xiaojie Tan, Yongwei Yu, Haitang Chen, Wenjun Chang, Jianguo Hou, Danfeng Xu, Liye Ma and Guangwen Cao

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26028

      • original image
      • original image
      • original image
      • original image

      Microsatellite alteration at marker D9S168 (9p23-22) in tumor DNA relative to normal DNA in tumor specimens independently predicted cancer-related death in patients with clear cell renal cell carcinoma (ccRCC) after curative nephrectomy. D9S168 alteration was associated significantly with low expression of protein tyrosine phosphatase receptor delta (PTPRD) in tumors, indicating that PTPRD is a candidate tumor suppressor in ccRCC.

    11. You have free access to this content
      Detection of second malignancies during long-term follow-up of testicular cancer survivors (pages 4212–4218)

      Tomas Buchler, Petra Kubankova, Ludmila Boublikova, Zuzana Donatova, Martin Foldyna, Jana Kanakova, Drahomira Kordikova, Martin Kupec, Jana Nepomucka, Eva Vorsilkova and Jitka Abrahamova

      Version of Record online: 8 APR 2011 | DOI: 10.1002/cncr.26039

      • original image
      • original image
      • original image

      Second cancers cause significant morbidity and mortality in testicular cancer survivors, but strategies for their early detection remain poorly defined. The authors describe the circumstances of diagnosis of second cancers in testicular cancer survivors. In their retrospective study, most cases of second cancers were missed using follow-up that included yearly history, physical examination, tumor markers, and imaging.

    12. You have free access to this content
      Secondary malignancies among nonseminomatous germ cell tumor cancer survivors (pages 4219–4230)

      Karim Chamie, Eric A. Kurzrock, Christopher P. Evans, Mark S. Litwin, Theresa M. Koppie, Sandra L. Wootton-Gorges, John M. Boone, Primo N. Lara Jr and Ralph W. deVere White

      Version of Record online: 15 MAR 2011 | DOI: 10.1002/cncr.26038

      • original image
      • original image

      With advancing age, patients who did not undergo retroperitoneal lymph node dissection (RPLND) for T1 or T2 clinical stage I nonseminomatous germ cell tumor (NSGCT) were more likely to develop a second malignancy and had worse survival than those who did undergo RPLND. The current results indicate that nonsurgical management of NSGCT may be associated with more long-term health risks than primary RPLND.

    13. Gynecologic Oncology
      You have free access to this content
      Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? (pages 4231–4237)

      Ellen W. Cooke, Lisa Pappas and David K. Gaffney

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26030

      • original image
      • original image
      • original image
      • original image
      • original image

      In a dataset of greater than 47,000 patients with endometrial adenocarcinoma, the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system produced better discrimination in cancer-specific survival outcomes compared with the 1988 FIGO staging system. In particular, the separation of stage IIIC into stages IIIC1 (pelvic lymph nodes) and IIIC2 (para-aortic lymph nodes) resulted in excellent discrimination in cause-specific survival outcomes.

    14. Hematologic Malignancies
      You have free access to this content
      Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia : Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006 (pages 4238–4246)

      Gunnar Juliusson, Karin Karlsson, Vladimir Lj Lazarevic, Anders Wahlin, Mats Brune, Petar Antunovic, Åsa Derolf, Hans Hägglund, Holger Karbach, Sören Lehmann, Lars Möllgård, Dick Stockelberg, Helene Hallböök, Martin Höglund and for the Swedish Acute Leukemia Registry Group, the Swedish Acute Myeloid Leukemia Group, the Swedish Adult Acute Lymphoblastic Leukemia Group

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26033

      • original image
      • original image
      • original image
      • original image

      Allogeneic stem cell transplantation rates for acute myeloid leukemia (AML) and acute lymphocytic leukemia were evaluated in the population-based Swedish Acute Leukemia Registry, covering 98% of all patients diagnosed from 1997 through 2006. More patients received allogeneic stem cell transplantation than in published international AML studies, and the high transplantation rate correlated with better long-term survival in AML, despite an unselected population with worse features.

    15. Hepatobiliary Disease
      You have free access to this content
      Longer leukocyte telomere length predicts increased risk of hepatitis b virus-related hepatocellular carcinoma : A case-control analysis (pages 4247–4256)

      Juan Liu, Yefa Yang, Hongxin Zhang, Siyuan Zhao, Hanqiang Liu, Naijian Ge, Hushan Yang, Jin-Liang Xing and Zhinan Chen

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26015

      • original image

      This study provides the first epidemiologic evidence linking long relative telomere length in peripheral blood leukocytes to an increased risk of hepatocellular carcinoma. The authors conclude that these findings warrant further investigation in other populations.

    16. Lung Disease
      You have free access to this content
      Clinicopathological features of lung adenocarcinoma with KRAS mutations (pages 4257–4266)

      Seiichi Kakegawa, Kimihiro Shimizu, Masayuki Sugano, Yohei Miyamae, Kyoichi Kaira, Takuya Araki, Tetsuhiro Nakano, Mitsuhiro Kamiyoshihara, Osamu Kawashima and Izumi Takeyoshi

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26010

      • original image
      • original image
      • original image

      KRAS mutated adenocarcinomas can be divided into 2 groups. The group without bronchioloalveolar elements is the classic KRAS mutated adenocarcinoma, which is related to smoking history and has a poor prognosis. Conversely, the group with bronchioloalveolar elements has a more favorable prognosis and little relationship with smoking exposure.

    17. Discipline

      Disparities Research
      You have free access to this content
      Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality (pages 4267–4276)

      Jennifer S. Haas, Phyllis Brawarsky, Aarthi Iyer, Garrett M. Fitzmaurice, Bridget A. Neville and Craig Earle

      Version of Record online: 16 MAR 2011 | DOI: 10.1002/cncr.26034

      Sociodemographic characteristics and measures of the availability of specialized cancer providers in the area in which an individual resides modestly mediated disparities in the receipt of colorectal cancer care and mortality.

    18. You have free access to this content
      Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors : A survival analysis (pages 4277–4285)

      Maxine Sun, Firas Abdollah, Daniel Liberman, Al'a Abdo, Rodolphe Thuret, Zhe Tian, Shahrokh F. Shariat, Francesco Montorsi, Paul Perrotte and Pierre I. Karakiewicz

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.25969

      • original image
      • original image
      • original image

      Racial and socioeconomic disparities predisposed men with testicular germ cell tumors (TGCTs) to more advanced disease stage at presentation and to higher mortality rates. The current results indicate that race-specific and socioeconomic status-specific adjustments in the treatment of patients with TGCTs are warranted.

    19. Pediatric Oncology
      You have free access to this content
      Response, survival, and toxicity after iodine-131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults (pages 4286–4293)

      Alexei L. Polishchuk, Steven G. DuBois, Daphne Haas-Kogan, Randall Hawkins and Katherine K. Matthay

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.25987

      • original image

      The authors present a retrospective, single-institution case series of 39 adolescent and adult patients ages ≥10 years with recurrent or refractory neuroblastoma who were treated with iodine-131–metaiodobenzylguanidine (131I-MIBG). Although the overall treatment response rate (46%) was high for all patients, the results demonstrate that adults had a significantly higher treatment response rate and exhibited a trend toward longer post-treatment overall survival compared with adolescents, indicating that 131I-MIBG is a promising salvage agent for neuroblastoma in this patient population.

    20. You have free access to this content
      The met and unmet health care needs of adult survivors of childhood central nervous system tumors : A double-informant, population-based study (pages 4294–4303)

      Emma Hovén, Birgitta Lannering, Göran Gustafsson and Krister K. Boman

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26020

      • original image
      • original image

      Findings based on reliable double-informant data indicate that a considerable percentage of adult survivors of childhood central nervous system tumors report unmet health care needs (HCNs). In the current study, risk groups regarding HCNs and unmet HCNs are identified, and avoidable causes of shortcomings in follow-up and issues critical for improved comprehensive follow-up care are verified.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Hematology/oncology fellows' training in palliative care : Results of a national survey (pages 4304–4311)

      Mary K. Buss, David S. Lessen, Amy M. Sullivan, Jamie Von Roenn, Robert M. Arnold and Susan D. Block

      Version of Record online: 1 MAR 2011 | DOI: 10.1002/cncr.25952

      • original image
      • original image

      In this national survey, hematology/oncology fellows rated the quality of palliative care education as inferior to overall oncology training. The results indicate that fellows may benefit from more teaching on pain management, psychosocial care, and communication skills and from improved integration of palliative care into their training.

    22. Translational Research
      You have free access to this content
      Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk : A meta-analysis (pages 4312–4324)

      Yonggang Zhang, Jie Zhang, Yao Deng, Can Tian, Xiaobo Li, Jin Huang and Hong Fan

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.25979

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The current results indicate that the +49 adenine/guanine polymorphism and the −318 cytosine/thymine polymorphism of the cytotoxic T-lymphocyte antigen 4 gene (CTLA-4) contribute to the risk of cancer. Future studies also should investigate gene-gene and gene-environment interactions to clarify the association between CTLA-4 polymorphisms and the risk of cancer.

    23. You have free access to this content
      Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome (pages 4325–4335)

      Cristina Bozzao, Patrizia Lastella, Maurizio Ponz de Leon, Monica Pedroni, Carmela Di Gregorio, Francesco D. D'Ovidio, Nicoletta Resta, Fernando Prete, Ginevra Guanti and Alessandro Stella

      Version of Record online: 8 MAR 2011 | DOI: 10.1002/cncr.26022

      • original image
      • original image
      • original image
      • original image

      The mean relative telomere length in DNA mismatch-repair gene mutation carriers did not differ from that in a group of normal controls. However, telomere attrition was accelerated significantly in mutS homolog 2 (MSH2) mutation carriers compared with controls and with mutL homolog 1 (MLH1) mutation carriers and was correlated with age at cancer onset.

SEARCH

SEARCH BY CITATION